ChemoMetec's Strategic Acquisition Plans
ChemoMetec has made a noteworthy move by extending an indicative offer to acquire Ovizio Imaging Systems. This plan aims to bolster ChemoMetec's footprint in the automated cell counting industry. The ownership group at Ovizio has accepted the offer, providing ChemoMetec a three-week window to carry out a detailed due diligence review. If all goes well, the acquisition is likely to proceed.
Spotlight on Innovative Technology
Ovizio specializes in cell counting technology that employs cutting-edge holographic microscopy. This advanced instrument is primarily used in bioprocessing and cell and gene therapy settings. One standout feature is its seamless integration with customers' bioreactors via a disposable component, which is sterilized and meets strict cleanliness standards. This setup facilitates continuous tracking of cell extraction from bioreactors, allowing for ongoing analysis and reintegration afterward, thus optimizing therapeutic workflows.
Insights into Customer Base and Revenue
With a customer base that includes notable companies in the pharmaceutical and biotechnology sectors, Ovizio has made a significant impact on the market. Last year, the company reported impressive revenue figures totaling EUR 1.4 million, a substantial part of which came from consumables and service contracts linked to its innovative technologies.
Synergy and Market Positioning
The management at ChemoMetec believes that merging their technologies with Ovizio's expertise will forge a strong partnership in the automated cell counting field. The synergies generated by this merger could lead to improved solutions for their customers and strengthen their competitive edge in the bioprocessing market.
Looking Ahead: Financial Guidance
While this acquisition could be advantageous, it's uncertain how it will affect ChemoMetec’s financial outlook for the fiscal year 2024/25. The management team is set to evaluate various factors in the forthcoming weeks to determine how this merger aligns with their long-term objectives.
About ChemoMetec A/S
Established in 1997, ChemoMetec develops, manufactures, and sells advanced instruments for cell counting and a variety of measurement tasks. Their tools are essential across multiple industries, including pharmaceuticals, biotechnology, and agriculture, catering to some of the leading pharmaceutical companies globally. ChemoMetec is publicly traded on Nasdaq OMX Copenhagen under the ticker Copenhagen:CHEMM.
Contact Information
If you have any further questions or require more details, please don’t hesitate to reach out to our leadership team:
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
Frequently Asked Questions
What is ChemoMetec planning with Ovizio Imaging Systems?
ChemoMetec has made an offer to acquire Ovizio Imaging Systems to enhance their automated cell counting technology and market position.
How does Ovizio's technology work?
Ovizio employs holographic microscopy for cell counting, which allows for real-time monitoring and analysis in bioprocessing and gene therapy.
What was Ovizio's revenue last year?
In the last reported year, Ovizio generated a revenue of EUR 1.4 million, primarily driven by consumables and service contracts.
How will the acquisition impact ChemoMetec's future?
The full effects on ChemoMetec's financial guidance for the 2024/25 fiscal year are still under review as they conduct due diligence.
Who can I contact for more information?
For more information, you can reach out to Martin Helbo Behrens, CEO, or Kim Nicolajsen, CFO, at the provided telephone numbers.
